Claims for Patent: 7,897,586

Summary for Patent: 7,897,586

Title:	Anaesthetic composition
Abstract:	A stable anaesthetic composition is described which is particularly suitable for use in cats and dogs. The composition comprises an aqueous solution of an anaesthetically effective amount of a water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone and a buffer, excluding phosphate buffer pH 7.0, 0.1M mixed as defined in the British Pharmacopoeia 1998, such that the pH of the solution is from 6.0-8.0.
Inventor(s):	Kieran; Peter John (Nelson\'s Bay, AU), Lau; Kai Kin (Dural, AU), Patten; Barry Edward (Panania, AU)
Assignee:	Jurox Pty. Ltd. (Rutherford, AU)
Application Number:	10/130,573
Patent Claims:	1. A stable anaesthetic composition which comprises an aqueous solution of an anaesthetically effective amount of a water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone and a citro-phosphate buffer, said buffer having a pH of 6.5, wherein crystalline material does not form in the composition within about 7 days when stored at 40.degree. C.; the water soluble cyclodextrin or cyclodextrin derivative is 2-hydroxypropyl beta-cyclodextrin; and the concentration of alfaxalone is 7-15 mg/mL. 2. A sterile ready-to-use dosage of an anaesthetic comprising a package which includes an anaesthetic composition as claimed in claim 1 and one or more antimicrobial agents. 3. A sterile dosage of an anaesthetic composition comprising a first package containing in dry form, an anaesthetically effective amount of a water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone and a citro-phosphate buffer, and a second package of sterile water, the buffer being selected such that a solution formed by dissolving the contents of the first package with contents of the second package has a pH of 6.5, wherein crystalline material does not form in the composition within about 7 days when stored at 40.degree. C.; the water soluble cyclodextrin or cyclodextrin derivative is 2-hydroxypropyl beta-cyclodextrin; and the concentration of alfaxalone is 7-15 mq/mL in the solution formed by dissolving the contents of the first package with contents of the second package. 4. A sterile dosage of an anaesthetic composition comprising a first package containing in dry form, an anaesthetically effective amount of a water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone, and a second package containing a sterile aqueous solution of a citro-phosphate buffer, the buffer being selected such that a solution formed by dissolving the contents of the first package with contents of the second package has a pH of 6.5, wherein crystalline material does not form in the composition within about 7 days when stored at 40.degree. C.; the water soluble cyclodextrin or cyclodextrin derivative is 2-hydroxypropyl beta-cyclodextrin; and the concentration of alfaxalone is 7-15 mg/mL in the solution formed by dissolving the contents of the first package with contents of the second package. 5. A sterile dosage of an anaesthetic composition comprising a package containing in dry form for reconstitution with sterile water, an anaesthetically effective amount of a water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone and a citro-phosphate buffer, the buffer being selected such that a solution formed by dissolving the contents of the package with sterile water has a pH of 6.5, wherein crystalline material does not form in the composition within about 7 days when stored at 40.degree. C.; the water soluble cyclodextrin or cyclodextrin derivative is 2-hydroxypropyl beta-cvclodextrin; and the concentration of alfaxalone is 7-15 mg/mL in the solution formed by dissolving the contents of the first package with contents of the second package. 6. A method of anaesthetising warm-blooded animals comprising administering to said animals an anaesthetically effective amount of a composition as claimed in claim 1. 7. A method of anaesthetising warm-blooded animals comprising administering to said animals an anaesthetically effective amount of the dosage of claim 2. 8. A method as in claim 6 or claim 7 wherein the animal is a dog or a cat. 9. An anaesthetic composition according to claim 1 consisting essentially of an aqueous solution of an anaesthetically effective amount of the water soluble cyclodextrin or a cyclodextrin derivative complex of alfaxalone and a citro-phosphate buffer, said buffer having a pH of 6.5. 10. A sterile dosage of an anaesthetic composition as claimed in claim 3 wherein said first package consists essentially of in dry form, an anaesthetically effective amount of the water soluble cyclodextrin or cyclodextrin derivative complex of alfaxalone and a citro-phosphate buffer, the buffer being selected such that a solution formed by dissolving the contents of the first package with contents of the second package has a pH of 6.5. 11. A sterile dosage of an anaesthetic composition as claimed in claim 4 wherein said first package consists essentially of in dry form, an anaesthetically effective amount of the water soluble cyclodextrin or cyclodextrin derivative complex of alfaxalone, and wherein said second package consists essentially of a sterile aqueous solution of a citro-phosphate buffer, the buffer being selected such that a solution formed by dissolving the contents of the first package with contents of the second package has a pH of 6.5. 12. A sterile dosage of an anaesthetic composition as claimed in claim 5 wherein said package consists essentially of in dry form for reconstitution with sterile water, an anaesthetically effective amount of the water soluble cyclodextrin or cyclodextrin derivative complex of alfaxalone and a citro-phosphate buffer, the buffer being selected such that a solution formed by dissolving the contents of the package with sterile water has a pH of 6.5.

Details for Patent 7,897,586

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2020-03-20